Meeting Highlights
Coverage of the 2008 Congress of the European League Against Rheumatism, Paris, France, June 11-14, 2008
Honolulu, September 14-19, 2007
Notes from the 2007 Meeting of the Global Arthritis Research Network
News from the 8th International Congress
Affiliations
MSK Report News
MSK Video:
Annmarie Lindahl, MD presents results from the Swedish EIRA study at the 2008 EULAR Congress
Floris Lafeber, PhD presents "Joint distraction in the treatment of severe knee osteoarthritis: the first results on clinical efficacy and structual repair" at the 2008 EULAR Congress
Wednesday, July 23, 2008
Consumer News:
Sunscreen Safety Is Called Into Question
After an environmental group questioned the safety of many popular sunscreen brands, consumers are left questioning which, if any, type of sunscreen they should use…
Tuesday, July 22, 2008
Consumer News:
Varicose, Spider Veins May Be Inevitable for Some
Although some perceive spider and varicose veins as a cosmetic concern, the condition can lead to serious health problems and may require surgical intervention…
Monday, July 21, 2008
News Analysis:
Congress Overrides Bush Veto of Medicare Bill, Stops Doc Fee Cuts, Requires Electronic Rx
Congress voted July 15 to override President George W. Bush's veto of the new Medicare bill, which now becomes law without his signature, stops a scheduled cut in fees paid to doctors, pushes hard for electronic prescribing, adds more drugs to the Medicare approved list, and dramatically changes Medicare payments for mental health services…
Friday, July 18, 2008
Arthritis:
Even Really Old Joints Benefit From Replacement in Osteoarthritis
Patients ≥75 do as well as those 65 to 74 after joint replacement for severe hip or knee OA...
Thursday, July 17, 2008
New from PubMed:
Classification and Categorization of Psoriatic Arthritis
Researchers in the field of psoriatic arthritis are working to overhaul Moll and Wright’s criteria for the classification and categorization of the disease…
Thursday, July 17, 2008
Arthritis:
New OA-Associated Gene Points to β-Tubulin Connection
Variants in a gene called DVWA may increase the risk of developing osteoarthritis...
Thursday, July 17, 2008
Consumer News:
Drugs to Build Bones May Weaken Them
A small group of people taking bisphosphonates for 5 or more years to treat osteoporosis have had their bones weakened by the drugs that are intended to promote better bone health…
BioPharm Business News
Tuesday, July 22, 2008
Compugen Reports Positive Preclinical Results for Therapeutic Peptide Candidate for Immune Related Diseases
The gp96 protein triggers both the innate and adaptive arms of the immune system and is thought to play a key role in inflammatory responses, making it an important target for therapeutic intervention in the treatment of immune-related disorders...
Tuesday, July 22, 2008
Ardea Biosciences Advances RDEA806 Into Phase IIa Proof-of-Concept Study for Gout
Ardea Biosciences has received regulatory approval to begin a phase IIa proof-of-concept clinical trial evaluating RDEA806 in gout patients with hyperuricemia...
Wednesday, July 16, 2008
Amgen Reports Positive Top-Line Results for Denosumab Treatment of Bone Loss in Men With Nonmetastatic Prostate Cancer Undergoing Androgen Deprivation Therapy; Study Met Primary, Secondary Endpoints
The improvements in BMD were consistent with those seen in other denosumab studies evaluating BMD in women with breast cancer receiving aromatase inhibitor therapy and in postmenopausal women with low bone mass...
Tuesday, July 15, 2008
Wyeth Reports European Commission Announces Marketing Authorization for 50 mg Once-Weekly Enbrel® (etanercept) for Patients With Moderate-to-Severe Psoriasis
The European Commission announced a new 50 mg Enbrel® (etanercept) once-weekly dosage regimen as an alternative to the currently approved 25 mg Enbrel twice-weekly regimen for the treatment of moderate-to-severe plaque psoriasis...
Monday, July 14, 2008
Welichem's Phase I Clinical Trial of Topical WBI-1001 Meets Primary, Secondary Objectives in Psoriasis
Welichem Biotech, a biotechnology company developing therapeutic drugs in the fields of autoimmune, inflammatory diseases, and cancer, announced positive results from a phase I clinical trialevaluating topically applied WBI-1001 in psoriasis patients...
